Table 3 Diagnostic performance of each analyte to predict <10th and < 3rd centile infants, and preeclampsia
Outcome | Analyte and cut-point | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|---|
Birthweight < 10th centile (All SGA) | sFlt-1 > 4570 pg/ml | 19.6% [12.4–28.6%] | 89.9% [84.9–93.6%] | 18.0% [11.1–27.9%] | 90.8% [89.8–91.6%] |
PlGF < 117.3 pg/ml | 28.8% [20.4–38.6%] | 89.5% [84.6–93.3%] | 24.2% [16.3–34.5%] | 91.6% [90.5–92.5%] | |
sFlt-1:PlGF > 33.4 | 26.5% [18.2–36.1%] | 89.9% [84.9–93.6%] | 22.9% [15.0–33.2%] | 91.5% [90.5–92.4%] | |
Birthweight < 10th centile (SGA only) | sFlt-1 > 4570 pg/ml | 16.8% [9.9–25.9%] | 89.9% [84.9–93.6%] | 14.8% [8.7–24.2%] | 91.1% [90.3–91.9%] |
PlGF < 117.3 pg/ml | 24.7% [16.5–34.5%] | 89.5% [84.6–93.3%] | 20.2% [13.0–30.0%] | 91.7% [90.7–92.6%] | |
sFlt-1:PlGF > 33.4 | 22.1% [14.2–31.8%] | 89.9% [84.9–93.6%] | 18.6% [11.6–28.5%] | 91.7% [90.7–92.5%] | |
Birthweight < 3rd centile (All SGA) | sFlt-1 > 4570 pg/ml | 21.4% [8.3–41.0%] | 87.5% [83.1–91.2%] | 4.7% [2.2–9.7%] | 97.5% [96.9–97.9%] |
PlGF < 117.3 pg/ml | 32.1% [15.9–52.4%] | 85.0% [80.3–88.9%] | 5.8% [3.3–10.1%] | 97.8% [97.1–98.3%] | |
sFlt-1:PlGF > 33.4 | 28.6% [13.2–48.7%] | 85.8% [81.1–89.6%] | 5.5% [2.9–10.0%] | 97.7% [97.0–98.1%] | |
Birthweight < 3rd centile (SGA only) | sFlt-1 > 4570 pg/ml | 22.2% [8.6–42.3%] | 88.7% [84.4–92.2%] | 5.2% [2.4–10.7%] | 97.6% [97.1–98.1%] |
PlGF < 117.3 pg/ml | 29.6% [13.8–50.2%] | 86.4% [81.9–90.2%] | 5.7% [3.1–10.4%] | 97.8% [97.2–98.3%] | |
sFlt-1:PlGF > 33.4 | 25.9% [11.1–46.3%] | 87.3% [82.7–91.0%] | 5.4% [2.7–10.3%] | 97.7% [97.1–98.2%] | |
Preeclampsia | sFlt-1 > 4570 pg/ml | 56.4% [39.6–72.2%] | 89.9% [84.9–93.6%] | 18.4% [12.1–26.9%] | 98.1% [97.3–98.6%] |
PlGF < 117.3 pg/ml | 64.1% [47.2–78.8%] | 89.5% [84.6–93.3%] | 19.9% [13.6–28.2%] | 98.4% [97.6–98.9%] | |
sFlt-1:PlGF > 33.4 | 69.2% [52.4–83.0%] | 89.9% [84.9–93.6%] | 21.7% [14.9–30.4%] | 98.6% [97.8–99.1%] |